FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4375853669> ?p ?o ?g. }

• W4375853669 endingPage "684" @default.
• W4375853669 startingPage "676" @default.
• W4375853669 abstract "Excessive daytime sleepiness (EDS) is common among patients with obstructive sleep apnea (OSA). The comparative effectiveness of pharmacologic agents is unknown.To compare the effectiveness of drugs for EDS in OSA using network meta-analysis.MEDLINE, CENTRAL, EMBASE, and ClinicalTrials.gov to 7 November 2022.Reviewers identified randomized trials that enrolled patients with EDS-associated OSA on or eligible for conventional therapy assigned to any pharmacologic intervention.Paired reviewers independently extracted data addressing effects of drugs on the Epworth Sleepiness Scale (ESS), Maintenance of Wakefulness Test (MWT), and adverse events at the longest reported follow-up. The certainty of evidence was assessed using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach.Fourteen trials (3085 patients) were eligible. At 4 weeks, compared with placebo, solriamfetol improves ESS scores (mean difference [MD], -3.85 [95% CI, -5.24 to -2.50]; high certainty), and armodafinil-modafinil (MD, -2.25 [CI, -2.85 to -1.64]; moderate certainty) and pitolisant-H3-autoreceptor blockers (MD, -2.78 [CI, -4.03 to -1.51]; moderate certainty) probably improve ESS scores. At 4 weeks, compared with placebo, solriamfetol (standardized mean difference [SMD], 0.9 [CI, 0.64 to 1.17]) and armodafinil-modafinil (SMD, 0.41 [CI, 0.27 to 0.55]) improve MWT (both high certainty), whereas pitolisant-H3-autoreceptor blockers probably do not (moderate certainty). At 4 weeks, armodafinil-modafinil probably increases the risk for discontinuation due to adverse events (relative risk [RR], 2.01 [CI, 1.14 to 3.51]; moderate certainty); solriamfetol may increase the risk for discontinuation due to adverse events (RR, 2.07 [CI, 0.67 to 6.25]; low certainty). Low certainty evidence suggests these interventions may not increase the risk for serious adverse events.There is limited evidence on long term or effectiveness among patients nonadherent or with mixed adherence to conventional OSA therapies.Solriamfetol, armodafinil-modafinil, and pitolisant reduce daytime sleepiness for patients with OSA already on conventional therapy, with solriamfetol likely superior. Adverse events probably increase the risk for discontinuation of armodafinil-modafinil and may increase the risk for discontinuation with solriamfetol.None." @default.
• W4375853669 created "2023-05-10" @default.
• W4375853669 creator A5012115646 @default.
• W4375853669 creator A5014222177 @default.
• W4375853669 creator A5015308739 @default.
• W4375853669 creator A5030043115 @default.
• W4375853669 creator A5031799727 @default.
• W4375853669 creator A5042646577 @default.
• W4375853669 creator A5063394859 @default.
• W4375853669 creator A5066491872 @default.
• W4375853669 date "2023-05-01" @default.
• W4375853669 modified "2023-10-18" @default.
• W4375853669 title "Comparative Efficacy and Safety of Wakefulness-Promoting Agents for Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea" @default.
• W4375853669 cites W144263799 @default.
• W4375853669 cites W1551995098 @default.
• W4375853669 cites W1902576439 @default.
• W4375853669 cites W1973058610 @default.
• W4375853669 cites W1975771352 @default.
• W4375853669 cites W1988112222 @default.
• W4375853669 cites W1994379541 @default.
• W4375853669 cites W1998672599 @default.
• W4375853669 cites W2011435303 @default.
• W4375853669 cites W2065513803 @default.
• W4375853669 cites W2089122724 @default.
• W4375853669 cites W2091808438 @default.
• W4375853669 cites W2100531908 @default.
• W4375853669 cites W2108987615 @default.
• W4375853669 cites W2117834225 @default.
• W4375853669 cites W2121213590 @default.
• W4375853669 cites W2121796373 @default.
• W4375853669 cites W2125043834 @default.
• W4375853669 cites W2127398647 @default.
• W4375853669 cites W2128103058 @default.
• W4375853669 cites W2136431713 @default.
• W4375853669 cites W2161061887 @default.
• W4375853669 cites W2165010366 @default.
• W4375853669 cites W2274636960 @default.
• W4375853669 cites W2314434775 @default.
• W4375853669 cites W2748830120 @default.
• W4375853669 cites W2760158714 @default.
• W4375853669 cites W2766211624 @default.
• W4375853669 cites W2785674771 @default.
• W4375853669 cites W2900579861 @default.
• W4375853669 cites W2905201451 @default.
• W4375853669 cites W2952751432 @default.
• W4375853669 cites W2959442417 @default.
• W4375853669 cites W2970684805 @default.
• W4375853669 cites W2978795816 @default.
• W4375853669 cites W2983079501 @default.
• W4375853669 cites W3000649099 @default.
• W4375853669 cites W3009627507 @default.
• W4375853669 cites W3015537361 @default.
• W4375853669 cites W3032147654 @default.
• W4375853669 cites W3072041319 @default.
• W4375853669 cites W3099906708 @default.
• W4375853669 cites W3099978774 @default.
• W4375853669 cites W3119116175 @default.
• W4375853669 cites W3129399780 @default.
• W4375853669 cites W3132408111 @default.
• W4375853669 cites W3136603761 @default.
• W4375853669 cites W4287092671 @default.
• W4375853669 cites W4307047863 @default.
• W4375853669 doi "https://doi.org/10.7326/m22-3473" @default.
• W4375853669 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37155992" @default.
• W4375853669 hasPublicationYear "2023" @default.
• W4375853669 type Work @default.
• W4375853669 citedByCount "2" @default.
• W4375853669 countsByYear W43758536692023 @default.
• W4375853669 crossrefType "journal-article" @default.
• W4375853669 hasAuthorship W4375853669A5012115646 @default.
• W4375853669 hasAuthorship W4375853669A5014222177 @default.
• W4375853669 hasAuthorship W4375853669A5015308739 @default.
• W4375853669 hasAuthorship W4375853669A5030043115 @default.
• W4375853669 hasAuthorship W4375853669A5031799727 @default.
• W4375853669 hasAuthorship W4375853669A5042646577 @default.
• W4375853669 hasAuthorship W4375853669A5063394859 @default.
• W4375853669 hasAuthorship W4375853669A5066491872 @default.
• W4375853669 hasConcept C118552586 @default.
• W4375853669 hasConcept C126322002 @default.
• W4375853669 hasConcept C142724271 @default.
• W4375853669 hasConcept C1513209611 @default.
• W4375853669 hasConcept C168563851 @default.
• W4375853669 hasConcept C204787440 @default.
• W4375853669 hasConcept C27081682 @default.
• W4375853669 hasConcept C2776006263 @default.
• W4375853669 hasConcept C2778205975 @default.
• W4375853669 hasConcept C2778664715 @default.
• W4375853669 hasConcept C2780714222 @default.
• W4375853669 hasConcept C2781210498 @default.
• W4375853669 hasConcept C2781326671 @default.
• W4375853669 hasConcept C2781433485 @default.
• W4375853669 hasConcept C42219234 @default.
• W4375853669 hasConcept C71924100 @default.
• W4375853669 hasConceptScore W4375853669C118552586 @default.
• W4375853669 hasConceptScore W4375853669C126322002 @default.
• W4375853669 hasConceptScore W4375853669C142724271 @default.
• W4375853669 hasConceptScore W4375853669C1513209611 @default.
• W4375853669 hasConceptScore W4375853669C168563851 @default.

• next